Prognostic Value Of Chemotherapy-Induced Neutropenia In Metastatic Colorectal Cancer At Rsup Dr Sardjito Yogyakarta

Muhammad Ihsan Qomaruzzaman; Johan Kurnianda; Mardiah Suci Hardianti

doi:10.22146/actainterna.27006

Prognostic Value Of Chemotherapy-Induced Neutropenia In Metastatic Colorectal Cancer At Rsup Dr Sardjito Yogyakarta

https://doi.org/10.22146/actainterna.27006

Muhammad Ihsan Qomaruzzaman^(1*), Johan Kurnianda⁽²⁾, Mardiah Suci Hardianti⁽³⁾

(1)
(2)
(3)
(*) Corresponding Author

Abstract

Background: Colorectal cancer is the third largest incidence of cancer in the world and is the third most common cause of death in women and men . Five-year overall survival (OS) in colorectal cancer who have undergone metastasis was 10 % . Hematologic toxicity may be a marker of biological activity of cytotoxic drug on various types of cancer . Neutropenia
after chemotherapy known to be associated with increased patient survival .
Objective : To establish whether chemotherapy-induced neutropenia is predictive of better outcome in patients with metastatic colorectal cancer (mCRC).
Methods: This research was a case-control study. Subjects were patients with metastatic colorectal cancer in the Cancer Instalation Center Tulip RSUP dr. Sardjito who meet the inclusion and exclusion criteria. Data were analyzed by bivariate analysis using chi square test and multivariate analysis with logistic regression.
Results: Neutropenia present in 26 patients (32.5%) of the total 80 patients of the study. Neutropenia were significantly affect OS ( p = 0.001 and OR 7.73, 95% CI: 2.51-23.80). Multivariate logistic regression analysis showed neutropenia and the number of metastases affect OS with p <0.001 and p <0.003.
Conclusion: Neutropenia occurring during the two first lines of chemotherapy for metastases colorectal cancer is associated with better survival. Variables that affect OS is the number of metastases and incidence of neutropenia after chemotherapy.

Keywords

Neutropenia, colorectal cancer, metastases, overall survival

Full Text:

PDF

References

Ferlay, J., Soerjomataram, I., Ervik, M,, Dikshit, R., Eser, S., Mathers, C., et al. 2012. Cancer Incidence and Mortality Worldwide: IARC

CancerBase No. 11 [Internet]. Lyon, France: International Agency

for Research on Cancer; 2013.

Haggar, F.A., Boushey, R.P., 2009. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clinics in Colon and Rectal Surgery 22 (4): 191-197.

Adam, R., Haller, G., Psoton, G., Raoul, J.L., Spano, J.P., Tabernero, J., et al., 2010. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer—an expert review from the International Congress on Anti- Cancer Treatment (ICACT). Annals of Oncology 21: 1579-1584.

Siegel, R., Jemal, A., 2013. Colorectal Cancer Facts & Figures 2011-2013. American Cancer Society, Atlanta, Georgia.

Wei liu, Cui-cui Zhang, Kai Li. 2013. Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer. Cancer Biol Med ; 10(2): 92–98.

Shitara, K., Matsuo, K., Oze,I., Mizota,A., Kondo,C., Nomura,M., et al., 2011. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 68:301–307.

Laurie, R., Bertaut, A., Vincent, J., Lorgis, V., Sylvain, L., Ghiringhelli, F.,2014. Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. World J

Gastroenterol; 20(6): 1565-1573

Yamanaka, T., Matsumoto, S., Teramukai, S., Ishiwata, R., Nagai, Y., Fukushima, M. 2007. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advancedgastric carcinoma. Br J Cancer ;97:37-42.

Gurney, H., 2002. How to calculate the dose of chemotherapy. Br J Cancer ;86:1297-1302.

Gamelin, E., Delva, R., Jacob, J., Merrouche, Y., Raoul, J.L., Pezet, D.,et al. 2008. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol ; 26: 2099-2105.

De Gramont,A., Figer, A., Seymour, M., 2000. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 18 (16): 2938–47.

Delord, J.P., Umlil, A., Guimbaud, R., Grégoire, N., Lafont, T., Canal, P., et al.,2003. Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol. 51: 127- 131.

Di Maio, M., Gridelli, C., Gallo, C., Shepherd, F., Piantedosi, F.V., Cigolari, S.,et al.2005. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol ; 6: 669-677.

Miyoshi, N., Yano, M., Takachi, K., Kishi, K., Noura, S., Eguchi, H., 2009. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. J Surg Oncol; 99: 302-306

DOI: https://doi.org/10.22146/actainterna.27006